ES2325431B1 - Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. - Google Patents

Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. Download PDF

Info

Publication number
ES2325431B1
ES2325431B1 ES200502511A ES200502511A ES2325431B1 ES 2325431 B1 ES2325431 B1 ES 2325431B1 ES 200502511 A ES200502511 A ES 200502511A ES 200502511 A ES200502511 A ES 200502511A ES 2325431 B1 ES2325431 B1 ES 2325431B1
Authority
ES
Spain
Prior art keywords
baselineskip
nucleotide sequence
sequence
gse
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200502511A
Other languages
English (en)
Spanish (es)
Other versions
ES2325431A1 (es
Inventor
Rosario Perona Abellon
Rosario Machado Pinilla
Leandro Sastre Garzon
Isabel Sanchez Perez
Jose Ramon Murguia Ibañez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Universitat Politècnica de València
Autonomous University of Madrid
Original Assignee
Consejo Superior de Investigaciones Científicas
Universitat Politècnica de València
Autonomous University of Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200502511A priority Critical patent/ES2325431B1/es
Application filed by Consejo Superior de Investigaciones Científicas, Universitat Politècnica de València, Autonomous University of Madrid filed Critical Consejo Superior de Investigaciones Científicas
Priority to DE602006014574T priority patent/DE602006014574D1/de
Priority to PT06849419T priority patent/PT1947175E/pt
Priority to ES06849419T priority patent/ES2360238T3/es
Priority to JP2008535049A priority patent/JP5560398B2/ja
Priority to US12/090,215 priority patent/US9074194B2/en
Priority to DK06849419.4T priority patent/DK1947175T3/da
Priority to PCT/ES2006/070152 priority patent/WO2007090911A1/es
Priority to AT06849419T priority patent/ATE469212T1/de
Priority to CA002625981A priority patent/CA2625981A1/en
Priority to EP06849419A priority patent/EP1947175B1/en
Publication of ES2325431A1 publication Critical patent/ES2325431A1/es
Application granted granted Critical
Publication of ES2325431B1 publication Critical patent/ES2325431B1/es
Priority to US14/740,890 priority patent/US9587002B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
ES200502511A 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. Expired - Fee Related ES2325431B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES200502511A ES2325431B1 (es) 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones.
AT06849419T ATE469212T1 (de) 2005-10-14 2006-10-11 Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase- aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon
ES06849419T ES2360238T3 (es) 2005-10-14 2006-10-11 Secuencias de nucleótidos y péptidos gse 24.2 de disquerina que puede inducir actividad de la telomerasa, procedimiento para obtener la misma, composiciones terapéuticas y aplicaciones de la misma.
JP2008535049A JP5560398B2 (ja) 2005-10-14 2006-10-11 テロメラーゼ活性を誘導するジスケリンのｇｓｅ２４．２ポリヌクレオチドおよびペプチドの配列、その取得方法、医薬組成物およびその使用方法
US12/090,215 US9074194B2 (en) 2005-10-14 2006-10-11 Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
DK06849419.4T DK1947175T3 (da) 2005-10-14 2006-10-11 Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf
DE602006014574T DE602006014574D1 (de) 2005-10-14 2006-10-11 Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase-aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon
PT06849419T PT1947175E (pt) 2005-10-14 2006-10-11 Sequência de nucleótidos e de péptidos gse 24.2 da disquerina, que podem induzir a actividade da telomerase, método para os obter, composições terapêuticas e suas aplicações
CA002625981A CA2625981A1 (en) 2005-10-14 2006-10-11 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
EP06849419A EP1947175B1 (en) 2005-10-14 2006-10-11 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
PCT/ES2006/070152 WO2007090911A1 (es) 2005-10-14 2006-10-11 Secuencia de nucleótidos y péptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtención, composiciones terapéuticas y sus aplicaciones
US14/740,890 US9587002B2 (en) 2005-10-14 2015-06-16 Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200502511A ES2325431B1 (es) 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones.

Publications (2)

Publication Number Publication Date
ES2325431A1 ES2325431A1 (es) 2009-09-03
ES2325431B1 true ES2325431B1 (es) 2010-06-28

Family

ID=38344881

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200502511A Expired - Fee Related ES2325431B1 (es) 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones.
ES06849419T Active ES2360238T3 (es) 2005-10-14 2006-10-11 Secuencias de nucleótidos y péptidos gse 24.2 de disquerina que puede inducir actividad de la telomerasa, procedimiento para obtener la misma, composiciones terapéuticas y aplicaciones de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06849419T Active ES2360238T3 (es) 2005-10-14 2006-10-11 Secuencias de nucleótidos y péptidos gse 24.2 de disquerina que puede inducir actividad de la telomerasa, procedimiento para obtener la misma, composiciones terapéuticas y aplicaciones de la misma.

Country Status (10)

Country Link
US (2) US9074194B2 (enExample)
EP (1) EP1947175B1 (enExample)
JP (1) JP5560398B2 (enExample)
AT (1) ATE469212T1 (enExample)
CA (1) CA2625981A1 (enExample)
DE (1) DE602006014574D1 (enExample)
DK (1) DK1947175T3 (enExample)
ES (2) ES2325431B1 (enExample)
PT (1) PT1947175E (enExample)
WO (1) WO2007090911A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334736B1 (es) * 2007-11-23 2011-02-02 Consejo Superior De Investigaciones Cientificas (Titular Al 90%) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
US20160051485A1 (en) * 2013-02-05 2016-02-25 Consejo Superior De Investigaciones (Csic) Biodegradable Bionanoparticles for Releasing the GSE24-2 Peptide, Method for the Production Thereof, and Use of Same
EP3061815B1 (en) * 2013-10-25 2020-02-19 Consejo Superior de Investigaciones Cientificas (CSIC) Peptides derived from gse 24.2 for treating diseases caused by oxidative stress and damage to dna
KR20220022126A (ko) * 2019-05-02 2022-02-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Tert 활성화 치료요법을 포함하는 방법 및 조성물
WO2024194500A1 (es) 2023-03-17 2024-09-26 Consejo Superior De Investigaciones Científicas (Csic) Péptido derivado de gse24.2 y usos del mismo
ES2989543A1 (es) * 2023-05-22 2024-11-26 Alodia Farm S L U Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054449A2 (de) * 1998-04-17 1999-10-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dyskerin und dafür codierende dna-moleküle, diese enthaltende vektoren, antikörper gegen dyskerin und die verwendung dieser gegenstände

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054449A2 (de) * 1998-04-17 1999-10-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dyskerin und dafür codierende dna-moleküle, diese enthaltende vektoren, antikörper gegen dyskerin und die verwendung dieser gegenstände

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KNIGHT, S.W., et al. "{}X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene"{}. AM. J. HUM. GENET. 27.05.1999. Vol. 65, páginas 50-58, todo el documento. *
VULLIAMY, T.J., et al. "{}Dyskeratosis congenita caused by a 3' deletion: Germline and somatic mosaicism in a female carrier"{}. BLOOD. 15.08.1999. Vol. 94, n$^{o}$ 4, páginas 1254-1260, todo el documento. *

Also Published As

Publication number Publication date
DK1947175T3 (da) 2010-09-27
US20150337022A1 (en) 2015-11-26
ES2360238T3 (es) 2011-06-02
DE602006014574D1 (de) 2010-07-08
CA2625981A1 (en) 2007-08-16
JP2009511036A (ja) 2009-03-19
US9074194B2 (en) 2015-07-07
EP1947175B1 (en) 2010-05-26
EP1947175A1 (en) 2008-07-23
ES2325431A1 (es) 2009-09-03
WO2007090911A1 (es) 2007-08-16
US20090202503A1 (en) 2009-08-13
US9587002B2 (en) 2017-03-07
PT1947175E (pt) 2010-09-02
JP5560398B2 (ja) 2014-07-23
ATE469212T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
US9587002B2 (en) Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
CN103800904A (zh) Hat乙酰化启动子和其组合物在促进免疫原性中的用途
Won et al. Human Noxin is an anti‐apoptotic protein in response to DNA damage of A549 non‐small cell lung carcinoma
KR102252423B1 (ko) 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
Fernandez-Garcia et al. Telomeres and telomerase in lung cancer
ES2334736B1 (es) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
Rapisarda et al. Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
CN106659911A (zh) 治疗或预防神经退行性病症的组合物和方法
Kanzawa et al. Down-regulation of telomerase activity in malignant glioma cells by p27KIP1
WO2019052000A1 (zh) 一种靶向STAT3信号通路miRNA及其制备方法和应用
Perona Abellón et al. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
US12194057B2 (en) NXTAR-derived oligonucleotides and uses thereof
Qiao et al. PKC promotes proliferation of airway smooth muscle cells by regulating cyclinD1 expression in asthmatic rats
KR101527749B1 (ko) miR-186, miR-216b, miR-337-3p 및 miR-760 억제제를 유효성분으로 포함하는 세포 노화 예방 또는 치료용 조성물
NZ569075A (en) Use of elF-5A to kill multiple myeloma cells
KR102864696B1 (ko) Upf1 단백질 또는 upf1 단백질 유래 폴리펩티드의 암의 예방 또는 치료 용도
KR100880850B1 (ko) 고형암 세포에서 사이클로필린 ａ의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법
SÁNCHEZ PÉREZ TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS
Zhou et al. Broad-spectrum antitumor analysis of the telomerase activity inhibitor TPCH derived from the human constitutively expressed protein LPTS/PinX1
Le Francois Mechanisms underlying thymidylate synthase regulation in human cells
WO2008112701A2 (en) G-substrate for the treatment and prevention of parkinson's disease
Young Overcoming replicative senescence in human cells and tissues using telomerase gene therapy
Yimam Identification and characterization of primate P-glycoprotein
WO2007013704A1 (en) Recombinant adeno-associated virus comprising antisense cdnas of vegf-a, vegf-b and vegf-c and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same
Sampathi New insights into the roles of DNA replication/repair proteins at telomeres

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20090903

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2325431B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180809